- Beyond Boston: Unlikely cities stake biotech claims<figure><div><img src="https://imgproxy.divecdn.com/lHTPvWvEMjW-n2hvHXgcGrQIAti_O2dHFFQGdwbcrzk/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjI2NDY4ODE4LmpwZ…BioPharma Dive · 19d ago↗ source
- STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and moreNovartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx BioSTAT · 19d ago↗ source
- The race for an Ebola therapy beginsMale marathoners "hit the wall," mental health in 2026, and more Morning Rounds newsSTAT · 19d ago↗ source